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Abstract
Background: Recent studies suggest that YKL-40, also called chitinase-3-like-1 protein, has been implicated in the
pathogenesis of various inflammatory diseases. It is currently unknown, however, whether YKL-40 plays a role in
acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and airway remodeling.
Methods: We evaluated serum YKL-40 levels in patients with AECOPD (n = 37) and stable COPD (n = 44), as well as
in controls (n = 47). The association between YKL-40 expression and airway remodeling was analyzed. The effects of
YKL-40 on collagen synthesis of primary human lung fibroblasts were also evaluated.
Results: Serum YKL-40 levels were elevated at AECOPD onset as compared to stable disease (median [interquartile
range], 78.6 [52.3–122.2] ng/ml versus 46.7 [31.2–75.5] ng/ml; p = 0.0005). The ideal cutoff point for distinguishing
patients with AECOPD from those with stable COPD was 64.7 ng/ml (AUC: 0.71; 95%CI: 0.596 to 0.823). YKL-40
expression correlated with airflow obstruction, C-reactive protein, and collagen deposition. Stimulation with YKL-40
promoted collagen production in lung fibroblasts through ERK- and p38-dependent mechanisms.
Conclusions: YKL-40 expression is up-regulated in patients with COPD and correlates with exacerbation attacks and
may contribute to airway remodeling by acting on lung fibroblasts. The current data may provide insight into the
underlying pathogenesis of COPD, in which YKL-40 has an important pathogenic role.
Trial registration: ChiCTR-OCC-13003567
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Background
Acute exacerbations of chronic obstructive pulmonary
disease (AECOPD) are common events that often lead
to hospital admissions, increased healthcare costs [1].
During exacerbation, COPD patients experience a wors-
ening of symptoms that coincides with accelerated de-
cline in lung function, resulting in a decrease in quality
of life. Airway inflammation plays a pivotal role in the
pathogenesis of AECOPD. However, methods used in
clinical practice are not appropriate for the evaluation of
airway inflammation [2, 3]. For example, spirometry is
used to monitor disease activity, but it has been shown
that spirometry is not closely associated with the levels
of inflammation. Thus, identification of novel bio-
markers associated with pathophysiologic changes in
COPD is necessary to improve the clinical management
of COPD for the benefit of the patients. Recently, several
questions have been raised about the role of the
chitinase-like protein YKL-40 in chronic bronchial in-
flammation. YKL-40 (also known as chitinase 3-like 1
(CHI3L1)) binds to the ubiquitously expressed chitin but
lacks chitinase activity. Previous studies have demon-
strated that YKL-40 is associated with various pathologic
conditions that are characterized by aberrant cell growth,
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tissue inflammation and remodeling, such as asthma, idio-
pathic pulmonary fibrosis (IPF) and allergic rhinitis [4–
15]. However, it is currently unknown whether YKL-40
plays a role in AECOPD.
Airway remodeling is another prominent pathophysio-
logic feature of COPD, which is characterized by thick-
ening of the airway wall with increased collagen
deposition [16]. The mechanisms underlying its develop-
ment have not been fully elucidated. The extent of
airway wall thickening is associated with disease progres-
sion, and this thickening is the major cause of decreased
lung function in COPD as remodeling reduces airflow
and distensibility [17–19]. Previous studies indicated
that serum YKL-40 levels were increased in severe
asthma patients and were correlated positively with the
thickness of the subepithelial basement membrane [8,
20–23]. Furuhashi et al. demonstrated that increased ex-
pression of YKL-40 was involved in tissue remodeling
and fibrosis in IPF patients [9]. Létuvé et al. suggested
that YKL-40 may influence extracellular matrix deposit
and turnover by inducing metal matrix proteinase
(MMP)-9 production by alveolar macrophages [12].
These data suggest that YKL-40 contributes to tissue re-
modeling in various human diseases. However, there is
no evidence that YKL-40 is involved in airway remodel-
ing in COPD. Lung fibroblasts have been shown to con-
tribute to airway remodeling in airway diseases through
synthesis and secretion of the main components of the
extracellular matrix (ECM), such as proteoglycans and
collagens [17]. Park et al. showed that YKL-40 induced
the increased production of transforming growth fac-
tor (TGF) beta1, MMP-9 and collagen production in
human nasal mucosa fibroblast [24]. Recklies et al.
also showed that YKL-40 was preferentially expressed
in areas with active fibrogenesis in patients with hep-
atic fibrosis, where it may act synergistically with
insulin-like growth factor I to stimulate the growth of
fibroblasts [14, 25]. However, whether YKL-40 partici-
pates in the onset of deposition of ECM and fibrosis
of the small airways in patients with COPD has not
been explored.
In the present study, we hypothesized that the up-
regulation of YKL-40 expression is more pronounced in
more severe forms of COPD and could induce airway re-
modeling by acting on human lung fibroblasts. Firstly,
we investigated the expression of YKL-40 in patients
with COPD and identified its correlation to acute ex-
acerbation, disease severity (e.g., lung function, arterial
blood gases) and airway remodeling. In addition, we
evaluated the proliferation, transformation and collagen
production from primary human lung fibroblasts in vitro
after stimulation with YKL-40. Finally, the potential
mechanism of YKL-40 action on collagen production in
human lung fibroblasts was explored.
Methods
Study population
From October 2013 to November 2014, a total of 81 pa-
tients with COPD as defined by the Global Initiative for
Chronic Obstructive Lung Disease guidelines (GOLD)
guidelines [1], who had a history of chronic respiratory
symptoms, such as cough and sputum with or without
breathlessness, had a postbronchodilator forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC) ratio of
less than 0.7 were recruited. Exclusion criteria were as fol-
lows: any chronic cardiopulmonary disease other than
COPD (including asthma); received oral or intravenous
corticosteroids or any other anti-inflammatory drugs in
the preceding four weeks, given the possibility that the
anti-inflammatory drugs may be able to suppress the ele-
vation of pulmonary YKL-40 levels to confound the re-
sults [26]; and an inability to give written informed
consent or cooperate with the study investigators. We also
recruited 47 age-matched healthy subjects with normal
spirometry from the communities surrounding our hos-
pital to serve as controls. They were free of respiratory
tract infection in the four weeks prior to the study. The
characteristic of the patients and controls are shown in
Table 1. COPD patients (n = 81) were divided into a stable
group (n = 44) and an exacerbation group (n = 37). The
division was based upon the status of the patients at the
time of the initial visit and those that were experiencing
an exacerbation at that time point compared to those that
were not. Stable COPD was defined as no change in their
treatment course for four or more weeks and also had no
evident acute exacerbations of COPD during that same
time period [1]. AECOPD was defined as an event in the
natural course of the disease characterized by a change in
the patient’s baseline dyspnea, cough, and/or sputum that
is beyond normal day-to-day variations, is acute in onset,
and may warrant a change in regular medication in a
patient with underlying COPD [1]. The patients with
AECOPD were followed up, and post-exacerbation sam-
ples were collected when the patients were on their usual
COPD treatment and at their baseline respiratory state.
The study protocol was approved by the Ethics of Re-
search Committee of the Medical College of Guangdong
and was registered on the Chinese Clinical Trial Database
(ChiCTR-OCC-13003567). Written informed consent was
obtained from all participants.
Sample collection
To investigated the expression of YKL-40 in the lung tis-
sue and identified its correlation to airway remodeling,
lung tissue specimens were obtained from patients who
were undergoing lung lobectomy for localized lung car-
cinoma (Additional file 1: Table S1). Specimens were
dissected at a distance of ≥ 5 cm away from the tumor.
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Laboratory measurements
Pulmonary function tests were performed according to
American Thoracic Society (ATS) guidelines either on
the same day as the bronchoscopy or on the day that the
serum samples were collected [27]. Blood gas analysis
was performed using a gas analyzer (IL GEM Premier
3000, USA). CRP was performed using ARRAY 360
automatic protein analyzer (BECKMAN, USA). The refer-
ence value of serum CRP concentration was 0–10 mg/L.
YKL-40 levels were measured using commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kits
(Uscn Life Science Inc., Wuhan, China). The minimum
detection limit of the YKL-40 assay was 13.1 pg/ml.
Immunohistochemistry
Details on the methods used to make these measure-
ments are provided in the Additional file 1. Quantitative
measurements of YKL-40 positive cells in the lung tissue
were performed according to previously described
methods [28]. YKL-40 positive cells were expressed as a
percentage of total cells. The intraobserver error was
assessed by performing three independent counts on the
same section on separate occasions. Sections were exam-
ined using a light microscope (BX51; Olympus, Japan)
and quantified by the Image Pro 6.1 software (Media
Cybernetics).
Quantitation of peribronchial collagen deposition
Peribronchial collagen deposition was detected by Mas-
son trichrome staining. The area of peribronchial Mas-
son trichrome staining (blue color) was visualized and is
quantified by the software as a percentage of the total
band area as previously described [29].
Human fibroblasts isolation and stimulation
Primary human lung fibroblasts were isolated from lung
tissue obtained from donors undergoing resection for lo-
calized lung carcinoma who gave informed consent, as
described previously [17]. The available clinical charac-
teristics of donors, including age, pack-years, and lung
function, are provided in Additional file 1: Table S1. All
experiments were carried out using cells between pas-
sage 3 and 6. Details on isolation and cultivation of hu-
man lung fibroblasts are also provided in the Additional
file 1.
Cell viability assays, migration and proliferation
To investigate cell viability, cells were seeded into a 96-
well plate at a density of 1 × 104 cells/well. The cells
were treated with different doses of recombinant human
YKL-40 protein (R&D Systems, Minneapolis, USA) for
48 h. A CCK-8 assay (Liankebio, Hangzhou, China) was
used to determine cell viability according to the
Table 1 Baseline characteristic of subjects













Age, yrs 57.7 ± 1.5 58.3 ± 1.0 56.8 ± 1.3 60.0 ± 1.5 0.402 0.116
Male/female, n 28/19 54/27 27/17 27/10 0.297 0.270
Smoking history, packs/year 37.0 ± 1.7 42.9 ± 1.2 41.6 ± 1.1 44.3 ± 2.3 0.067 0.258
Smoking statusNever/current/former, n 25/12/10 0/49/32 0/28/16 0/21/16 0.420 0.528
FEV1/FVC, % 82.9 ± 0.8 53.1 ± 1.4 56.1 ± 1.8 49.7 ± 2.2 <0.001 0.027
FEV1, % predicted 96.6 ± 1.6 54.7 ± 2.4 61.4 ± 3.2 46.7 ± 3.3 <0.001 0.002
PaO2, mmHg N/D 74.2 ± 1.0 77.5 ± 1.0 70.3 ± 1.5 ― <0.001
PaCO2, mmHg N/D 43.1 ± 0.6 40.6 ± 0.7 45.9 ± 0.9 ― <0.001
CRP, mg/L 3.5 ± 0.3 36.7 ± 3.6 14.2 ± 1.1 63.5 ± 4.5 <0.001 <0.001
Severity of COPDa N/A ― 0.489
GOLD I/II, n (%) 47 (58.0) 24 (54.5) 23 (62.2)
GOLD III/IV, n (%) 34 (42.0) 20 (45.5) 14 (37.8)
COPD treatments, n (%) N/A ― 0.935
ICS/LABA 58 (71.6) 32 (72.7) 26 (70.3)
SABA or SAMA 71 (87.7) 38 (86.4) 33 (89.2)
Theophylline 51 (63.0) 29 (65.9) 22 (59.5)
Data are presented as mean ± SEM, unless otherwise stated
aCOPD severity was graded into GOLD I, Mild (FEV1 ≥ 80 % predicted); GOLD II, Moderate (50 % ≤ FEV1 < 80 % predicted); GOLD III, Severe (30 % ≤ FEV1 < 50 %
predicted); and GOLD IV, Very severe (FEV1 < 30 % predicted) following the GOLD
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, PaO2 arterial partial oxygen pressure, PaCO2 arterial partial carbon dioxide pressure, CRP C reactive
protein, COPD chronic obstructive pulmonary disease, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, LABA long-acting β
agonist, SABA short-acting β agonist, SAMA short-acting muscarinic agonist, N/D not done, N/A not applicable
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manufacturer’s instructions. A ‘scratch-wound’ assay was
used to assess fibroblast migration fibroblast as de-
scribed previously [30]. Full details of this method are
available in the Additional file 1.
Western blotting assay
Western blot analysis was used to detect changes in col-
lagen type I, collagen type III, α-SMA, ERK, phosphory-
lated ERK (p-ERK), p38 and phosphorylated (p-p38)
(Cell Signaling Technology, USA) as previously de-
scribed [31].
Statistical analysis
Data were presented as the mean ± SEM, unless other-
wise stated. Statistical analysis was performed using
SPSS 17.0 (SPSS, Chicago, IL, USA) and GraphPad
Prism 5.0 software (GraphPad Software Inc., San Diego,
CA, USA). Statistical significance was set at a p value <
0.05. Full details are available in the Additional file 1.
Results
Clinical data
Table 1 shows the main clinical and functional charac-
teristics of the subjects in the study. There was no sig-
nificant difference in age, gender or smoking status.
Compared with patients in the stable group and control
group, those in the exacerbation group had lower lung
function (p = 0.002) and PaO2 levels (p < 0.001) but
higher PaCO2 levels (p < 0.001) and serum CRP levels
(p < 0.001). Similar proportions of subjects were re-
ceiving medications in both groups (p = 0.935).
Serum YKL-40 levels were elevated during an AECOPD
The serum YKL-40 levels for patients in smokers with
COPD were higher than those in smokers without
COPD (median [interquartile range], 60.80 [34.7–90.1]
ng/ml versus 22.7 [15.6–36.4] ng/ml; p < 0.001) and
those in never-smoker individuals (78.60 [52.3–90.11]
ng/ml versus 20.9 [15.2–26.3] ng/ml; p < 0.001) (Fig. 1a).
The serum YKL-40 and CRP levels of COPD patients in
the exacerbation group were higher than those in stable
group (YKL-40: 78.6 [52.3–122.2] ng/ml versus 46.7
[31.2–75.5] ng/ml; p = 0.0005; CRP: 60.0 [39.9–93.4] mg/
L versus 16.9 [13.0–23.8] mg/L; p < 0.001) (Fig. 1b, c).
Moreover, serum levels of YKL-40 were positively corre-
lated with CRP (r = 0.601, p < 0.001) (Fig. 1d). Spearman
rank correlation coefficient showed that borderline sig-
nificance was evident between YKL-40 concentrations
and pack-years (r = 0.224, p = 0.045) (Fig. 1e). During the
follow-up visit, five AECOPD patients were lost to
follow-up because they refused to continue participating.
Finally, 32 subjects completed the study and were
Fig. 1 Serum YKL-40 levels in patients with COPD and controls. Serum YKL-40 was increased in smokers with COPD (defined as COPD (+)) compared
with smokers without COPD (defined as COPD (−)) and non-smokers (a); When patients were stratified according to exacerbation attacks, the serum
YKL-40 and C-reactive protein (CRP) levels in patients in the exacerbation group were higher than those in the stable group (b, c); Spearman rank
correlation coefficient showed that YKL-40 was positively associated with CRP (d); Borderline significance was evident between YKL-40 concentrations
and pack-years (r = 0.224, p = 0.045) (e); Patients in the exacerbation group, after acute exacerbations, demonstrated decreased serum YKL-40 levels
compared with those during AECOPD (f); Receiver operating characteristic (ROC) curve for distinguishing patients with AECOPD from those with stable
COPD. The area under the ROC curve was 0.71 (95%CI: 0.596 to 0.823). Horizontal bars represent median values (g)
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included in the data analyses. We found that patients in
the exacerbation group, after acute exacerbations, dem-
onstrated decreased serum YKL-40 levels compared with
those during AECOPD (54.3 [36.4–74.4] ng/ml versus
77.7 [50.9–113.9] ng/ml; p = 0.008) (Fig. 1f ). The ideal
cutoff point for distinguishing patients with AECOPD
from those with stable COPD was 64.7 ng/ml (sensitiv-
ity, 64.8 %; specificity, 71.2 %; AUC, 0.71; 95%CI: 0.596
to 0.823) (Fig.1g). YKL-40 levels may be affected by age
and gender. Thus, we further analyzed the between-
group differences following adjustment for age and gen-
der using multiple regression analyses. We found that
the AECOPD patients had significantly higher serum
YKL-40 levels than stable COPD patients, even after ad-
justment for sex, age. In addition, women had lower
serum YKL-40 levels, whereas older age was associated
with higher serum YKL-40 concentrations (Additional
file 1: Table S2).
Serum YKL-40 levels in COPD patients were correlated
with clinical parameters
Spearman’s rank correlation analysis showed that serum
YKL-40 levels in COPD patients were correlated nega-
tively with FEV1 and PaO2. However, there were no sig-
nificant correlations between serum YKL-40 levels and
other clinical parameters, such as the FEV1/FVC or
PaCO2 (Table 2).
Increased YKL-40 expression was positively correlated
with collagen deposition
Examination of lung tissue sections from patients who
were undergoing lung lobectomy for peripheral carcin-
oma showed that smokers with COPD, the percentage
of YKL-40 positive cells (27.1 [21.9–34.2]%) was signifi-
cantly increased than those without COPD (16.8 [13.9–
20.8]%; p = 0.002) and non-smokers (14.2 [9.4–17.9]%;
p < 0.001) (Fig. 2a–c, e). No immunostaining was ob-
served in control isotype IgG-treated tissue sections
(D). Detailed examination of the cellular sources of
YKL-40 in lung tissue revealed that a high level of
expression of YKL-40 in macrophages and neutrophils
(Fig. 2f–m). Collagen deposition in the lungs was in-
creased in smokers with COPD (56.5 [45.6–68.5]%)
compared to smokers without COPD (33.2 [21.2–44.9]%;
p = 0.001) and non-smokers (25.9 [22.3–32.7]%; p < 0.001)
(Fig. 3a-d). Furthermore, collagen deposition correlated
with YKL-40 expression in lung tissues (r = 0.57; p < 0.001)
(Fig. 3e).
YKL-40 can stimulate the proliferation, differentiation and
collagen synthesis in human lung fibroblast
The migration of human lung fibroblast cells was evalu-
ated by a scratch wound assay. Treatment with YKL-40
significantly increased the number of human lung fibro-
blast cells as compared to the untreated control (Fig. 4a-
b). Treatment with YKL-40 also increased the migration
capacity of human lung fibroblast cells compared with
the untreated control (Fig. 4c-d). The upregulation of α-
SMA expression is a characteristic marker for differenti-
ation of lung fibroblasts to myofibroblasts [23]. Using
immunofluorescence and western blotting, we detected
the expression of α-SMA in human lung fibroblast cells
after 48 h of treatment with YKL-40 (10 and 100 ng/ml)
and found that it significantly increased α-SMA protein
expression in a concentration-dependent manner com-
pared with the untreated control cells (Fig. 5). Treatment
with YKL-40 (100 ng/ml) also significantly increased the
expression of collagen I and III production compared with
untreated control fibroblast cells (Fig. 6).
Increased phosphorylation of p-38 and ERK in YKL-40-
induced collagen production
The mitogen-activated protein kinase (MAPK) family is
well known to play a key role in mediating inflammatory
responses [32]. To assess whether MAPK pathways are
involved in YKL-40-induced collagen production, the ef-
fect of YKL-40 on activation of ERK and p38 was evalu-
ated by western blotting. As shown in Fig. 7, stimulation
of human lung fibroblast cells with YKL-40 resulted in a
transient phosphorylation of ERK and p38. In addition,
YKL-40 activated ERK and p38 phosphorylaton in a
dose-dependent manner.
Table 2 Correlation between serum YKL-40 levels and clinical parametersa
Parameters Serum YKL-40
Stable (n = 44) Exacerbation (n = 37) All (n = 81)
rs P value rs P value rs P value
FEV1, % of predicted −0.399 0.007 −0.440 0.006 −0.442 <0.001
FEV1/FVC, % −0.156 0.356 −0.01 0.944 −0.201 0.072
CRP, mg/L 0.507 <0.001 0.624 <0.001 0.601 <0.001
PaO2, mmHg −0.349 0.020 −0.60 <0.001 −0.556 <0.001
PaCO2, mmHg 0.018 0.917 0.087 0.573 0.185 0.098
aSpearman’s rank order method. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, CRP C reactive protein, PaO2 arterial partial oxygen pressure,
PaCO2 arterial partial carbon dioxide pressure
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Discussion
In the present study, we further explored the potential
role of YKL-40 measurement in the management of
COPD. Our study indicated that YKL-40 levels were in-
creased in patients with COPD during exacerbation, and
the elevated YKL-40 was associated positively with CRP
and negatively with FEV1 and PaO2. Importantly, our
findings revealed that the expression of YKL-40 in lung
tissues of COPD patients was correlated with deposition
of collagen in the airway walls and induced lung fibro-
blast activation, suggesting that a potential mechanism
of small airway remodeling in COPD.
COPD is accompanied by systemic inflammation that
occurs as a result of many mechanisms, particularly air-
way inflammation and smoking [33–35]. Previous studies
indicated that YKL-40 was increased in many inflamma-
tory diseases that were accompanied by tissue destruction.
TNF-α stimulated YKL-40 synthesis in alveolar macro-
phages, and exposure of these cells to YKL-40 promoted
the release of IL-8, monocyte chemoattractant protein
(MCP)-1, macrophage inflammatory protein (MIP)-1α,
and metalloproteinase-9 [12]. We found that serum YKL-
40 levels were increased in COPD compared with smokers
without COPD and non-smokers. When the COPD sub-
jects were stratified, serum YKL-40 levels in the
exacerbation group were higher than those in the stable
group, which suggested that serum levels of YKL-40 cor-
related with COPD exacerbation attacks. Previous study
by Nordenbaek et al. has shown that serum YKL-40 re-
flects a different aspect of the inflammatory pulmonary
process than conventional acute-phase proteins [36]. CRP
is increased during bacterial infections which could be the
cause of the exacerbations in the patients with COPD.
CRP levels are useful in evaluating COPD exacerbation
[37]. Consistent with previous studies, we found that the
serum YKL-40 levels and CRP were elevated in patients
with AECOPD. Moreover, the serum YKL-40 levels corre-
lated positively with serum CRP levels. These findings in-
dicated that YKL-40 has a potential effect on the
pathogenesis of inflammation of COPD and may serve as
a specific serologic marker of granulocyte function at the
site of tissue inflammation as a supplement to conven-
tional acute-phase proteins [36]. Gumus et al. showed that
high serum YKL-40 level is related to hypoxemia and
hypoxia-related mediators may cause systemic inflamma-
tion in COPD [38]. We also found that serum YKL-40
levels correlated inversely with PaO2 as well as FEV1.
However, borderline significance was evident between
YKL-40 concentrations and pack-years. These findings are
consistent with those reported by Matsuura and
Fig. 2 YKL-40 was expression in lung tissues and localized within macrophages and neutrophils. Very faint staining for YKL-40 was observed in
the non-smokers (a); In the smokers without COPD, there were more YKL-40 positive cells in the lung parenchyma (b); Smokers with COPD had
considerably more YKL-40 positive cells staining in the lung parenchyma (expressed as a percentage of total cells) (c); No immunostaining was
observed in control isotype IgG-treated tissue sections (d); Quantification of YKL-40 expression in lung tissues (e); Confocal microscopy showed
localization of YKL-40 (green fluorescence) within CD68 or CD45 positive cells (red fluorescence) of the tissue sections (f-i and j-m, respectively).
(all images are × 400 magnification). Horizontal bars represent median values
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colleagues [10]. These results suggested that concentra-
tions of circulatory YKL-40 in patients with COPD are
profoundly affected by other local or systemic factors in
addition to cigarette smoke (CS) exposure [10].
Peribronchiolar fibrosis is an important feature of
COPD and is resulted from the increased extracellular
matrix deposition [12]. Collagens are the classical compo-
nents of the extracellular matrix. Collagens are synthetized
primarily by fibroblasts as precursor molecules with the
propeptides being cleaved during the process of secretion
of the newly formed collagens [39]. YKL-40 has been
shown to be a growth factor for mesenchymal cells that
contributes to degradation of extracellular matrix and tis-
sue remodeling [20–24]. Moreover, YKL-40 acts a chemo-
attractant for endothelial cells, and modulates vascular
endothelial cell morphology by promoting the formation
of branching tubules [9]. Previous studies indicated that
YKL-40 promoted reticular basement membrane (RBM)
thickening in severe asthma and contributed to tissue
remodeling and fibrosis in IPF patients [9, 20–22]. Col-
lectively, these data suggest that increased levels of YKL-
40 contribute to the pathologic process of human diseases
with tissue remodeling. Therefore, we further hypothe-
sized that YKL-40 might promote collagen desposition
and airway remodeling in COPD. We examined the ex-
pression of YKL-40 in small airways from smokers with
COPD and controls by immunohistochemistry. There was
a significant increase in YKL-40 expression in small air-
ways of smokers with COPD and correlated closely with
deposition of collagen. These data suggest that YKL-40
may be associated with small airway remodeling, a finding
that could help elucidate the mechanism of small airway
remodeling in COPD.
Recent studies have shown that YKL-40 is preferentially
expressed in areas with active fibrogenesis in patients with
hepatic fibrosis, where it may act synergistically with
insulin-like growth factor I to stimulate the growth of fi-
broblasts [12]. YKL-40 may also contribute to fibrosis by
Fig. 3 Collagen deposition in small airways from non-smokers, smokers without COPD and smokers with COPD. Photomicrographs of blue staining
showing collagen expression around the small airway walls from non-smokers (a), smokers without COPD (b), and smokers with COPD (c) (all images
are × 400 magnification); Measurement of collagen deposition in small airways. Smokers with COPD showed increased collagen deposition compared
to both the non-smokers, smokers without COPD (d); Collagen deposition was positively correlated with serum YKL-40 levels (r = 0.57; p < 0.001) (e).
Horizontal bars represent median values
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Fig. 4 The effect of YKL-40 treatment on the proliferation and migration of human lung fibroblast cells. The cells were treated with 0, 10 or
100 ng/ml YKL-40 for 48 h, then resuspended and counted (a); The cells were treated with 0, 10 or 100 ng/ml YKL-40 for 0 h, 24 h and 48 h, then
cell viability was measured with CCK-8 assay. Increased number of YKL-40-treated fibroblasts versus control fibroblasts was observed (b). Representative
images of human lung fibroblast cells treated with YKL-40 or untreated, at time 0 and after 48 h of incubation were shown. Increased fibroblast
migration was observed in YKL-40-treated fibroblasts versus control fibroblasts (c). Results are expressed as percentage of recovered wound area (d).
Results were expressed as mean ± SEM (n = 4 per group) of three independent experiments. *p < 0.05, **p < 0.01 compared with basal
Fig. 5 The effect of YKL-40 treatment on α-SMA protein expression in lung fibroblast cells. Lung fibroblast cells were treated with 0, 10 or
100 ng/ml YKL-40 for 48 h. Measurements of α-SMA expression upon stimulation by YKL-40 as determined by immunofluorescence staining (a),
and Western blot analysis (b); Analysis by densitometry of immunodetection of α-SMA (c). Results were expressed as mean ± SEM of three
independent experiments
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Fig. 6 The effect of YKL-40 on collagen synthesis in lung fibroblast cells. Lung fibroblast cells were treated with 0, 10 or 100 ng/ml YKL-40 for
48 h. Collagen I and collagen III production were determined by immunofluorescence staining (a), and Western blot analysis (b); Analysis by
densitometry of immunodetection of collagen I and collagen III (c, d). Results were expressed as mean ± SEM of three independent experiments
Fig. 7 YKL-40 induced phosphorylation of extracellular signal related kinase (ERK), and p38 in lung fibroblast cells. Recombinant human YKL-40 protein
activated ERK and p38 phosphorylaton in a dose-dependent manner (0, 1, 10, 50, 100 and 200 ng/ml for 2 h) (a); Stimulation of lung fibroblast cells with
50 ng/ml of recombinant human YKL-40 protein also induced phosphorylation of ERK and p38 in a time-dependent manner (0, 5, 15, 30, 60, 120 min) (b)
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modulating the rate of type I collagen fibril formation
[40]. However, whether YKL-40 participates in the onset
of fibrosis of the small airways in patients with COPD re-
mains to be determined. On the basis of the above find-
ings, we were prompted to further explore the role of
YKL-40 in collagen production in human lung fibroblasts
in vitro. As expected, we found that treatment with YKL-
40 increased proliferation, migration, collagen secretion
and α-SMA expression in human lung fibroblasts. Our re-
sults were consistent with previous work demonstrating
that YKL-40 are able to increase ECM, such as proteogly-
cans and collagens in nasal mucosa fibroblast [24]. Given
the role of YKL-40 in collagen production in human lung
fibroblasts, we sought to determine the key signaling
mechanisms by which this occurs. We demonstrated that
MAPK signaling was required for YKL-40-induced colla-
gen production in human lung fibroblasts. Taken together,
we presume that YKL-40 could activate lung fibroblasts
and its downstream MAPK pathway, and promote prolif-
eration and collagen production, which may enhance the
progression of small airway remodeling in COPD.
There are some limitations to this study that need to be
considered. First, exposure to YKL-40 significantly up-
regulated proliferation from fibroblasts obtained from
non-smokers, smokers without COPD and smokers with
COPD. Although there was a trend to up-regulated prolif-
eration from fibroblasts obtained from smokers with
COPD, there were no significantly difference among these
different patient groups (Additional file 1: Figure S1). Due
to the relatively small sample size, we could not precisely
analyze the fibroblasts from these different patient groups
behaved differently regarding their responses towards
YKL-40. Future studies with larger sample sizes as well as
animal experiments should be performed to clarify this
issue as it may suggest a target for therapeutic interven-
tion in future. Second, it is well known that tumors attract
macrophages which are critical in influencing tumor
growth and metastasis [41, 42]. Previous study showed
that YKL-40 is synthesized by activated macrophages [43].
Although resected normal tissues more than 5 cm away
from the tumor in our study, it should be noted that tu-
mors attract macrophages which are critical in influencing
tumor growth and metastasis and YKL-40 is synthesized
by activated macrophages. Therefore, the expression of
YKL-40 in lung tissues should be interpreted cautiously
due to this limitation.
Conclusions
In summary, the current findings demonstrate that ele-
vated YKL-40 levels are associated with acute exacerba-
tions and airway remodeling in patients with COPD.
Moreover, the in vitro data show that YKL-40 may pro-
mote airway remodeling in COPD by acting on human
lung fibroblasts. Overall, the current data may provide
insight into the underlying pathogenesis of COPD, in
which YKL-40 has an important pathogenic role.
Additional file
Additional file 1: YKL-40 expression in chronic obstructive pulmonary
disease: relation to acute exacerbations and airway remodeling. Table S1.
Characteristics of patients undergoing lung resection. Table S2. A
multivariable linear regression model predicting the YKL-40 levels in patients
with AECOPD and patients with stable COPD adjusted for sex, age. Figure S1.
The effect of YKL-40 treatment on the proliferation of human lung fibroblast
cells from non-smokers, smokers without COPD and smokers with COPD.
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